Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Geiges

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Der Urologe. Ausg. A|November 18, 2005
[Study participation in urological specialty practices]G Geiges, A Böhle, H Rexer
Aktuelle Urologie|July 27, 2013
[Value of intermittent androgen deprivation in the context of the current data situation]K Miller, P Hammerer, R Eichenauer, et al.
Der Urologe. Ausg. A|July 15, 2016
[Metastatic castration-resistant prostate cancer : Clinical data, new treatment options and therapy monitoring]K Miller, P Albers, R Eichenauer, et al.
Der Urologe. Ausg. A|May 9, 2014
[Metastatic castration-resistant prostate cancer: position paper for structured therapy monitoring]K Miller, P Albers, R Eichenauer, et al.
Aktuelle Urologie|May 31, 2006
[Interdisciplinary recommendations concerning the therapy for hormone-refractory prostatic carcinoma]K Miller, K Becker, F Finke, et al.
Der Urologe. Ausg. A|February 11, 2003
[European Association of Urology guidelines on urinary and male genital tract infections]P Schneede, A G Hofstetter, K G Naber, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Der Urologe. Ausg. A|November 18, 2005
[Study participation in urological specialty practices]G Geiges, A Böhle, H Rexer
Aktuelle Urologie|July 27, 2013
[Value of intermittent androgen deprivation in the context of the current data situation]K Miller, P Hammerer, R Eichenauer, et al.
Der Urologe. Ausg. A|July 15, 2016
[Metastatic castration-resistant prostate cancer : Clinical data, new treatment options and therapy monitoring]K Miller, P Albers, R Eichenauer, et al.
Der Urologe. Ausg. A|May 9, 2014
[Metastatic castration-resistant prostate cancer: position paper for structured therapy monitoring]K Miller, P Albers, R Eichenauer, et al.
Aktuelle Urologie|May 31, 2006
[Interdisciplinary recommendations concerning the therapy for hormone-refractory prostatic carcinoma]K Miller, K Becker, F Finke, et al.
Der Urologe. Ausg. A|February 11, 2003
[European Association of Urology guidelines on urinary and male genital tract infections]P Schneede, A G Hofstetter, K G Naber, et al.
Pageof 1